Literature DB >> 10225904

Inverse relationship between severity of experimental pyelonephritis and nitric oxide production in C3H/HeJ mice.

B Nowicki1, J Singhal, L Fang, S Nowicki, C Yallampalli.   

Abstract

The contribution of nitric oxide to host resistance to experimental pyelonephritis is not well understood. We examined whether the inhibition of nitric oxide synthesis alters the sensitivity of lipopolysaccharide (LPS) responder (C3H/HeN) and nonresponder (C3H/HeJ) mice to experimental Escherichia coli pyelonephritis. C3H/HeJ and C3H/HeN mice were implanted subcutaneously with minipumps containing an inhibitor of nitric oxide, NG-nitro-L-arginine methyl ester (L-NAME), or a corresponding vehicle. Ascending urinary tract infection by bladder catheterization with two strains of E. coli, an O75 strain bearing Dr fimbriae and an O75 strain bearing P fimbriae, was developed in tested animals. Twenty-four hours following bladder infection, the kidneys of C3H/HeN and C3H/HeJ mice were colonized at a similar rate. However, 5 weeks postinoculation, C3H/HeN mice cleared infection while C3H/HeJ mice showed persistent colonization. Twenty-four hours following infection, C3H/HeN mice treated with L-NAME showed no significant increase of renal tissue infection compared to the saline-treated control group. However, L-NAME-treated C3H/HeJ mice showed an approximately 100-fold increase in E. coli infection rate compared to the saline-treated controls in the Dr+ group but showed no change compared to those in the P+ group. Dissemination of Dr+ E. coli but not P+ E. coli to the liver and uterus was significantly enhanced with L-NAME treatment in C3H/HeJ mice only. Nitric oxide had no direct killing effect on E. coli in vitro. Nitrite production by various organs was found to be significantly lower in C3H/HeJ mice than in C3H/HeN mice. Alteration of nitric oxide and LPS responsiveness was significantly associated with the increased sensitivity of C3H/HeJ mice to experimental Dr+ but not to P+ E. coli pyelonephritis. These findings are consistent with the hypothesis that nitric oxide synthase activity in concert with LPS responsiveness may participate in the antibacterial defense mechanisms of the C3H mouse urinary tract. This phenomenon is strain dependent and possibly related to the invasive properties of E. coli.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225904      PMCID: PMC115987     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  42 in total

Review 1.  Lectinophagocytosis: a molecular mechanism of recognition between cell surface sugars and lectins in the phagocytosis of bacteria.

Authors:  I Ofek; N Sharon
Journal:  Infect Immun       Date:  1988-03       Impact factor: 3.441

2.  A hemagglutinin of uropathogenic Escherichia coli recognizes the Dr blood group antigen.

Authors:  B Nowicki; J Moulds; R Hull; S Hull
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

Review 3.  The role of bacterial vaginosis as a cause of amniotic fluid infection, chorioamnionitis and prematurity--a review.

Authors:  J Martius; D A Eschenbach
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

4.  Epithelial autotoxicity of nitric oxide: role in the respiratory cytopathology of pertussis.

Authors:  L N Heiss; J R Lancaster; J A Corbett; W E Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

5.  Bacterial virulence versus host resistance in the urinary tracts of mice.

Authors:  C Svanborg-Edén; L Hagberg; R Hull; S Hull; K E Magnusson; L Ohman
Journal:  Infect Immun       Date:  1987-05       Impact factor: 3.441

6.  Inhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia.

Authors:  C Yallampalli; R E Garfield
Journal:  Am J Obstet Gynecol       Date:  1993-11       Impact factor: 8.661

7.  Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide.

Authors:  D J Stuehr; M A Marletta
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

8.  An L-arginine-nitric oxide-cyclic guanosine monophosphate system exists in the uterus and inhibits contractility during pregnancy.

Authors:  C Yallampalli; H Izumi; M Byam-Smith; R E Garfield
Journal:  Am J Obstet Gynecol       Date:  1994-01       Impact factor: 8.661

9.  Interleukin-8 and the neutrophil response to mucosal gram-negative infection.

Authors:  W W Agace; S R Hedges; M Ceska; C Svanborg
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

10.  Nitric oxide mediates immune dysfunction in the spontaneously hypertensive rat.

Authors:  D W Pascual; V H Pascual; K L Bost; J R McGhee; S Oparil
Journal:  Hypertension       Date:  1993-02       Impact factor: 10.190

View more
  13 in total

1.  Structural and functional lesions in brush border of human polarized intestinal Caco-2/TC7 cells infected by members of the Afa/Dr diffusely adhering family of Escherichia coli.

Authors:  I Peiffer; J Guignot; A Barbat; C Carnoy; S L Moseley; B J Nowicki; A L Servin; M F Bernet-Camard
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

2.  Maternal/fetal mortality and fetal growth restriction: role of nitric oxide and virulence factors in intrauterine infection in rats.

Authors:  Katarzyna Wroblewska-Seniuk; Stella Nowicki; Chantal Le Bouguénec; Bogdan Nowicki; Chandra Yallampalli
Journal:  Am J Obstet Gynecol       Date:  2011-02-23       Impact factor: 8.661

3.  Caffeic acid phenethyl ester suppresses oxidative stress in Escherichia coli-induced pyelonephritis in rats.

Authors:  Sefa Celik; Sadik Gorur; Ozkan Aslantas; Suat Erdogan; Sabahattin Ocak; Sibel Hakverdi
Journal:  Mol Cell Biochem       Date:  2006-10-19       Impact factor: 3.396

Review 4.  Pathogenesis of Afa/Dr diffusely adhering Escherichia coli.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

Review 5.  Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

6.  Tumor necrosis factor alpha- and inducible nitric oxide synthase-producing dendritic cells are rapidly recruited to the bladder in urinary tract infection but are dispensable for bacterial clearance.

Authors:  Daniel Engel; Ulrich Dobrindt; André Tittel; Petra Peters; Juliane Maurer; Ines Gütgemann; Brigitte Kaissling; William Kuziel; Steffen Jung; Christian Kurts
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

7.  Epithelial invasion by Escherichia coli bearing Dr fimbriae is controlled by nitric oxide-regulated expression of CD55.

Authors:  Li Fang; Bogdan J Nowicki; Petri Urvil; Pawel Goluszko; Stella Nowicki; Steven L Young; Chandrasekhar Yallampalli
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

8.  UpaG, a new member of the trimeric autotransporter family of adhesins in uropathogenic Escherichia coli.

Authors:  Jaione Valle; Amanda N Mabbett; Glen C Ulett; Alejandro Toledo-Arana; Karine Wecker; Makrina Totsika; Mark A Schembri; Jean-Marc Ghigo; Christophe Beloin
Journal:  J Bacteriol       Date:  2008-04-18       Impact factor: 3.490

9.  Toll-like receptor 4-defective C3H/HeJ mice are not more susceptible than other C3H substrains to infection with Mycobacterium tuberculosis.

Authors:  Arati B Kamath; Jennifer Alt; Hajer Debbabi; Samuel M Behar
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

10.  Role of transcription factor Sp1 and RNA binding protein HuR in the downregulation of Dr+ Escherichia coli receptor protein decay accelerating factor (DAF or CD55) by nitric oxide.

Authors:  Manu Banadakoppa; Daniel Liebenthal; David E Nowak; Petri Urvil; Uma Yallampalli; Gerald M Wilson; Aparna Kishor; Chandra Yallampalli
Journal:  FEBS J       Date:  2013-01-02       Impact factor: 5.542

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.